Striatal Dopamine Transporter Binding Assessed by [I-123]IPT and Single Photon Emission Computed Tomography in Patients With Early Parkinson's Disease

Abstract

Use of [I-123] IPT and single photon emission computed tomography demonstrates a reduction of dopamine transporter binding in patients with early Parkinson's disease. Significantly reduced IPT binding already observed in the ipsilateral striatum of patients with Hoehn and Yahr stage I demonstrates the potential of this method to detect preclinical disease.

Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: A PET study

“…No significant reductions are evident in the caudate regions of the disease group. These observations agree with the previous ROI results presented by us and others from PET and SPECT studies of several radioligands (Guttman et al, 1997;Kazumata et al, 1998;Schwarz et al, 2000;Tissingh et al, 1998a). Both demonstrate bilaterally reduced DAT levels at early stage PD with an asymmetry between the ipsilateral and contralateral sides of the putamen.…”

Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: A PET study

“…No significant reductions are evident in the caudate regions of the disease group. These observations agree with the previous ROI results presented by us and others from PET and SPECT studies of several radioligands (Guttman et al, 1997;Kazumata et al, 1998;Schwarz et al, 2000;Tissingh et al, 1998a). Both demonstrate bilaterally reduced DAT levels at early stage PD with an asymmetry between the ipsilateral and contralateral sides of the putamen.…”

Impaired online and enhanced offline motor sequence learning in individuals with Parkinson’s disease

“…Although overt clinical symptoms were limited to a single upper limb, there is certainly a possibility that disease-related alterations in striatal circuitry were present -albeit to different degrees -in both striatal hemispheres at the time of testing. This would be consistent with previous research demonstrating PD-related pathology before the onset of clinical symptoms (Marsden, 1990;Fearnley and Lees, 1991;Braak et al, 2003Braak et al, , 2006Siderowf and Lang, 2012) as well as earlier imaging work showing changes in corticostriatal regions contralateral to the non-affected hand (Marek et al, 1996;Schwarz et al, 2000;Tessa et al, 2013).…”

Presynaptic dopaminergic function in patients with restless legs syndrome: Are there common features with early Parkinson's disease?

“…The typical SPECT finding in PD, as described here also, is reduced striatal DAT binding, even in early disease 17, 18. In our study, individual binding ratios of RLS patients were higher than were those of PD patients and not different from those in age‐matched controls.…”

Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: A PET study

“…No significant reductions are evident in the caudate regions of the disease group. These observations agree with the previous ROI results presented by us and others from PET and SPECT studies of several radioligands (Guttman et al, 1997;Kazumata et al, 1998;Schwarz et al, 2000;Tissingh et al, 1998a). Both demonstrate bilaterally reduced DAT levels at early stage PD with an asymmetry between the ipsilateral and contralateral sides of the putamen.…”

Impaired online and enhanced offline motor sequence learning in individuals with Parkinson’s disease

“…Although overt clinical symptoms were limited to a single upper limb, there is certainly a possibility that disease-related alterations in striatal circuitry were present -albeit to different degrees -in both striatal hemispheres at the time of testing. This would be consistent with previous research demonstrating PD-related pathology before the onset of clinical symptoms (Marsden, 1990;Fearnley and Lees, 1991;Braak et al, 2003Braak et al, , 2006Siderowf and Lang, 2012) as well as earlier imaging work showing changes in corticostriatal regions contralateral to the non-affected hand (Marek et al, 1996;Schwarz et al, 2000;Tessa et al, 2013).…”

Presynaptic dopaminergic function in patients with restless legs syndrome: Are there common features with early Parkinson's disease?

“…The typical SPECT finding in PD, as described here also, is reduced striatal DAT binding, even in early disease 17, 18. In our study, individual binding ratios of RLS patients were higher than were those of PD patients and not different from those in age‐matched controls.…”

Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: A PET study

“…No significant reductions are evident in the caudate regions of the disease group. These observations agree with the previous ROI results presented by us and others from PET and SPECT studies of several radioligands (Guttman et al, 1997;Kazumata et al, 1998;Schwarz et al, 2000;Tissingh et al, 1998a). Both demonstrate bilaterally reduced DAT levels at early stage PD with an asymmetry between the ipsilateral and contralateral sides of the putamen.…”

Impaired online and enhanced offline motor sequence learning in individuals with Parkinson’s disease

“…Although overt clinical symptoms were limited to a single upper limb, there is certainly a possibility that disease-related alterations in striatal circuitry were present -albeit to different degrees -in both striatal hemispheres at the time of testing. This would be consistent with previous research demonstrating PD-related pathology before the onset of clinical symptoms (Marsden, 1990;Fearnley and Lees, 1991;Braak et al, 2003Braak et al, , 2006Siderowf and Lang, 2012) as well as earlier imaging work showing changes in corticostriatal regions contralateral to the non-affected hand (Marek et al, 1996;Schwarz et al, 2000;Tessa et al, 2013).…”

Presynaptic dopaminergic function in patients with restless legs syndrome: Are there common features with early Parkinson's disease?

“…The typical SPECT finding in PD, as described here also, is reduced striatal DAT binding, even in early disease 17, 18. In our study, individual binding ratios of RLS patients were higher than were those of PD patients and not different from those in age‐matched controls.…”